Campbell & CO Investment Adviser LLC Acquires New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Campbell & CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,619 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Centessa Pharmaceuticals by 35.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock worth $99,999,000 after acquiring an additional 1,834,973 shares during the period. Armistice Capital LLC acquired a new position in Centessa Pharmaceuticals during the 1st quarter worth $6,730,000. Affinity Asset Advisors LLC increased its holdings in Centessa Pharmaceuticals by 41.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,546,662 shares of the company’s stock worth $22,241,000 after purchasing an additional 450,738 shares during the period. Cutter Capital Management LP raised its position in Centessa Pharmaceuticals by 184.3% in the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock valued at $6,013,000 after purchasing an additional 271,051 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $3,273,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on CNTA shares. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Friday, August 29th. They issued an “outperform” rating and a $40.00 target price on the stock. Wells Fargo & Company increased their price objective on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Guggenheim restated a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $33.11.

Insider Transactions at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $22.41, for a total value of $134,460.00. Following the completion of the sale, the general counsel directly owned 105,386 shares of the company’s stock, valued at $2,361,700.26. This represents a 5.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mario Alberto Accardi sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the transaction, the insider owned 194,394 shares in the company, valued at $4,859,850. This represents a 3.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 179,964 shares of company stock worth $4,106,481. Corporate insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Trading Down 1.1%

Shares of Centessa Pharmaceuticals stock opened at $27.32 on Tuesday. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The company has a fifty day simple moving average of $23.36 and a 200-day simple moving average of $17.65. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -14.93 and a beta of 1.56. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $29.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.